Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity (Met-IER)

13. september 2019 oppdatert av: King's College London

A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity

An intermittent energy restricted (IER) diet may modify cardio-metabolic disease risk factors compared to an energy-matched continuous energy restricted (CER) diet. A randomised controlled parallel design trial will determine the impact of a short-term IER diet (2 consecutive days of very low calorie diet (VLCD), 5 days moderate energy restriction each week for a 4 week period), compared to a CER diet, on insulin sensitivity in healthy (disease-free) subjects with central obesity.

Studieoversikt

Detaljert beskrivelse

Prediabetes rates in England have showed a marked increase, more than tripling between 2003 and 2011. It is characterised by an impaired fasting glucose or impaired glucose tolerance that increases the risk of progression to type 2 diabetes (T2D). It has been estimated that approximately 90% of T2D is attributed to excess weight. Central obesity is a primary driver of increased cardiometabolic risk due to its lipotoxicity effects, promoting a proinflammatory state that facilitates insulin resistance and beta cell dysfunction. A high waist circumference measurement, indicative of central obesity, is associated with increased risk of cardiovascular diseases and T2D, and is a stronger predictor of T2D than BMI. BMI has limitations as an indicator of adiposity since it doesn't distinguish lean from fat mass, and does not indicate body fat distribution. Conventionally, continuous energy restriction (CER) diets have been used for weight loss, which consist of a constant daily energy deficit relative to total energy expenditure. The impact on weight loss and health of an intermittent energy restriction (IER) approach has only rarely been investigated (although the "5:2 diet" has been popularised in lifestyle books aimed at the general public). An IER diet consists of a predefined period of time severely restricting energy intake, alternated with a period of greater energy intake. This approach was shown to confer metabolic benefits in overweight and obese women at risk of breast cancer with baseline BMI of 2445 (Harvie et al., 2013; Harvie et al., 2011).

Rationale: An IER diet using meal replacements (VLCD foodpacks used as total dietary replacements for 2 consecutive days each week, and a food-based energy-restricted diet for the other 5 days of the week) may modify cardio-metabolic disease risk factors compared to an energy-matched CER diet.

Research question: In centrally obese subjects, assessed by a high waist circumference measurement, does adherence to an IER diet have enhanced cardio-metabolic benefits compared to a CER diet? Hypothesis: Increases in insulin sensitivity following a 4 week dietary intervention with an IER weight loss programme will be greater compared to a standard CER programme.

Objectives:

  1. A randomised controlled parallel design trial will determine the impact of a short-term IER diet compared to a CER diet on primary outcome variables (insulin sensitivity) in healthy subjects with a high waist circumference.
  2. To assess the impact of an IER diet on secondary outcome variables, including body composition, heart rate variability (HRV, a measure of cardiac autonomic function, including parasympathetic and sympathetic activity), blood pressure, vascular function, other markers of insulin resistance, inflammation/adipokines, plasma lipid profile, plasma norepinephrine, ketosis, the gut microbiome and cognitive function in healthy subjects with a high waist circumference.

Studietype

Intervensjonell

Registrering (Faktiske)

42

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • England
      • London, England, Storbritannia, SE1 9NH
        • Diabetes & Nutritional Sciences Division, King's College London, Franklin-Wilkins Buiding, 150 Stamford St.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

35 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Aged >35-75 years
  • Waist circumference above cut-off for high risk of cardio-metabolic disease of >102 cm in men with a Europid, Black African and Caribbean, and other ethnic background and >88 cm in women with a Europid, Black African and Caribbean, and other ethnic background (WHO, 2008), and ≥90 cm in men and ≥80 cm in women with an Asian background (South Asian and East Asian) (Misra et al., 2009).

REFERENCES Misra A, Chowbey P, Makkar BM, Vikram NK, Wasir JS, Chadha D, et al. (2009). Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. The Journal of the Association of Physicians of India 57: 163170.

WHO (2008). Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva, 8-11 December 2008.

Exclusion Criteria:

  • Kidney or cardiovascular disease, cancer, diabetes, gastrointestinal or chronic liver disease;
  • previous bariatric surgery or other major surgery (e.g. organ transplantation);
  • unable to provide written informed consent;
  • have significant psychiatric disorder (e.g. schizophrenia, anxiety, panic disorder, attention deficit disorder, post-traumatic stress disorder, obsessive compulsive disorder) or uncontrolled depression;
  • participated in a weight management drug trial in the previous 3 months;
  • have binge eating behaviour;
  • have uncontrolled epilepsy;
  • alcohol or substance abuse;
  • currently pregnant, lactating, or planning pregnancy within the study period;
  • are using medication clinically deemed to affect metabolic rate and weight (e.g. beta blockers, corticosteroids, diuretics, etc);
  • lactose intolerant.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Forebygging
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Intermittent Energy Restriction
Weight loss intervention: Intermittent Energy Restriction
Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
Aktiv komparator: Continuous Energy Restriction
Weight loss intervention: Continuous Energy Restriction
Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Revised QUICKI (RQUICKI)
Tidsramme: Baseline
Marker of insulin sensitivity
Baseline
RQUICKI
Tidsramme: day 29
Marker of insulin sensitivity
day 29
RQUICKI
Tidsramme: day 31
Marker of insulin sensitivity
day 31

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Kroppsvekt
Tidsramme: Grunnlinje
Grunnlinje
Midjeomkrets
Tidsramme: Grunnlinje
Grunnlinje
Hofteomkrets
Tidsramme: Grunnlinje
Grunnlinje
Plasma glukosekonsentrasjon
Tidsramme: Grunnlinje
Fasting
Grunnlinje
Plasma adiponectin konsentrasjon
Tidsramme: Grunnlinje
Fasting
Grunnlinje
Plasma leptinkonsentrasjon
Tidsramme: Grunnlinje
Fasting
Grunnlinje
Plasma total kolesterolkonsentrasjon
Tidsramme: Grunnlinje
Fasting
Grunnlinje
Plasma lavdensitet lipoprotein (LDL) kolesterolkonsentrasjon
Tidsramme: Grunnlinje
Fasting
Grunnlinje
Plasma høydensitet lipoprotein (HDL) kolesterolkonsentrasjon
Tidsramme: Grunnlinje
Fasting
Grunnlinje
Plasma triglyseridkonsentrasjon
Tidsramme: Grunnlinje
Fasting
Grunnlinje
Totalt kolesterol i plasma: HDL-kolesterolforhold
Tidsramme: Grunnlinje
Fasting
Grunnlinje
Kroppsmasseindeks (BMI)
Tidsramme: Grunnlinje
Grunnlinje
Plasma glucose concentration
Tidsramme: day 29
Fasting
day 29
Plasma glucose concentration
Tidsramme: day 31
Fasting
day 31
Plasma insulin concentration
Tidsramme: Baseline
Fasting
Baseline
Plasma insulin concentration
Tidsramme: day 29
Fasting
day 29
Plasma insulin concentration
Tidsramme: day 31
Fasting
day 31
Plasma non-esterified fatty acid concentration
Tidsramme: Baseline
Fasting
Baseline
Plasma non-esterified fatty acid concentration
Tidsramme: day 29
Fasting
day 29
Plasma non-esterified fatty acid concentration
Tidsramme: day 31
Fasting
day 31
Plasma total cholesterol concentration
Tidsramme: day 29
Fasting
day 29
Plasma total cholesterol concentration
Tidsramme: day 31
Fasting
day 31
Plasma LDL cholesterol concentration
Tidsramme: day 29
Fasting
day 29
Plasma LDL cholesterol concentration
Tidsramme: day 31
Fasting
day 31
Plasma HDL cholesterol concentration
Tidsramme: day 29
Fasting
day 29
Plasma HDL cholesterol concentration
Tidsramme: day 31
Fasting
day 31
Plasma triglyceride concentration
Tidsramme: day 29
Fasting
day 29
Plasma triglyceride concentration
Tidsramme: day 31
Fasting
day 31
Plasma total cholesterol:HDL cholesterol ratio
Tidsramme: day 29
Fasting
day 29
Plasma total cholesterol:HDL cholesterol ratio
Tidsramme: day 31
Fasting
day 31
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Tidsramme: Baseline
Fasting (calculated from insulin and glucose)
Baseline
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Tidsramme: day 29
Fasting (calculated from insulin and glucose)
day 29
Homeostasis model assessment estimated insulin resistance (HOMA-IR)
Tidsramme: day 31
Fasting (calculated from insulin and glucose)
day 31
Plasma adiponectin concentration
Tidsramme: day 29
Fasting
day 29
Plasma adiponectin concentration
Tidsramme: day 31
Fasting
day 31
Plasma leptin concentration
Tidsramme: day 29
Fasting
day 29
Plasma leptin concentration
Tidsramme: day 31
Fasting
day 31
Plasma interleukin-6 concentration
Tidsramme: Baseline
Fasting
Baseline
Plasma interleukin-6 concentration
Tidsramme: day 29
Fasting
day 29
Plasma interleukin-6 concentration
Tidsramme: day 31
Fasting
day 31
Plasma beta-hydroxybutyrate concentration
Tidsramme: Baseline
Fasting
Baseline
Plasma beta-hydroxybutyrate concentration
Tidsramme: day 29
Fasting
day 29
Plasma beta-hydroxybutyrate concentration
Tidsramme: day 31
Fasting
day 31
Plasma norepinephrine concentration
Tidsramme: Baseline
Fasting
Baseline
Plasma norepinephrine concentration
Tidsramme: day 29
Fasting
day 29
Plasma norepinephrine concentration
Tidsramme: day 31
Fasting
day 31
Plasma soluble alpha-klotho concentration
Tidsramme: Baseline
Fasting
Baseline
Plasma soluble alpha-klotho concentration
Tidsramme: day 29
Fasting
day 29
Plasma soluble alpha-klotho concentration
Tidsramme: day 31
Fasting
day 31
Body weight
Tidsramme: day 29
day 29
Body weight
Tidsramme: day 31
day 31
BMI
Tidsramme: day 29
day 29
BMI
Tidsramme: day 31
day 31
Waist circumference
Tidsramme: day 29
day 29
Waist circumference
Tidsramme: day 31
day 31
Hip circumference
Tidsramme: day 29
day 29
Hip circumference
Tidsramme: day 31
day 31
Percentage body fat
Tidsramme: Baseline
Baseline
Percentage body fat
Tidsramme: day 29
day 29
Percentage body fat
Tidsramme: day 31
day 31
Percentage lean body mass
Tidsramme: Baseline
Baseline
Percentage lean body mass
Tidsramme: day 29
day 29
Percentage lean body mass
Tidsramme: day 31
day 31
Heart rate variability (resting)
Tidsramme: Baseline
supine
Baseline
Heart rate variability (resting)
Tidsramme: day 29
supine
day 29
Heart rate variability (resting)
Tidsramme: day 31
supine
day 31
Heart rate variability (ambulatory)
Tidsramme: 24 h recording at baseline
24 h recording at baseline
Heart rate variability (ambulatory)
Tidsramme: 24 h recording on day 29
24 h recording on day 29
Heart rate variability (ambulatory)
Tidsramme: 24 h recording on day 31
24 h recording on day 31
Heart rate variability (sleep-time)
Tidsramme: Baseline
Baseline
Heart rate variability (sleep-time)
Tidsramme: day 29
day 29
Heart rate variability (sleep-time)
Tidsramme: day 31
day 31
Heart rate variability (during mental stress)
Tidsramme: Baseline
Baseline
Heart rate variability (during mental stress)
Tidsramme: day 29
day 29
Heart rate variability (during mental stress)
Tidsramme: day 31
day 31
Ambulatory blood pressure 24 h
Tidsramme: 24 h analysis at baseline
24 h analysis at baseline
Ambulatory blood pressure daytime
Tidsramme: Daytime analysis at baseline
Daytime analysis at baseline
Ambulatory blood pressure night-time
Tidsramme: Night-time analysis at baseline
Night-time analysis at baseline
Ambulatory blood pressure 24 h
Tidsramme: 24 h analysis on day 29
24 h analysis on day 29
Ambulatory blood pressure daytime
Tidsramme: daytime analysis on day 29
daytime analysis on day 29
Ambulatory blood pressure night-time
Tidsramme: night-time analysis on day 29
night-time analysis on day 29
Ambulatory blood pressure 24 h
Tidsramme: 24 h analysis on day 31
24 h
24 h analysis on day 31
Ambulatory blood pressure daytime
Tidsramme: Daytime analysis on day 31
day time
Daytime analysis on day 31
Ambulatory blood pressure night-time
Tidsramme: Night-time analysis on day 31
night-time
Night-time analysis on day 31
Digital volume pulse - stiffness index (SI)
Tidsramme: Baseline
Stiffness index
Baseline
Digital volume pulse - SI
Tidsramme: day 29
Stiffness index
day 29
Digital volume pulse - SI
Tidsramme: day 31
Stiffness index
day 31
Digital volume pulse - reflection index (RI)
Tidsramme: Baseline
reflection index
Baseline
Digital volume pulse - RI
Tidsramme: day 29
reflection index
day 29
Digital volume pulse - RI
Tidsramme: day 31
reflection index
day 31
Mnemonic Similarity Test
Tidsramme: Baseline
Baseline
Mnemonic Similarity Test
Tidsramme: day 29
day 29
Mnemonic Similarity Test
Tidsramme: day 31
day 31
Power of food scale
Tidsramme: Baseline
questionnaire
Baseline
Power of food scale
Tidsramme: day 29
questionnaire
day 29
Power of food scale
Tidsramme: day 31
questionnaire
day 31
COPE (not an acronym)
Tidsramme: Baseline
questionnaire
Baseline
COPE
Tidsramme: day 29
questionnaire
day 29
COPE
Tidsramme: day 31
questionnaire
day 31

Andre resultatmål

Resultatmål
Tidsramme
Adverse events
Tidsramme: Baseline until endpoint: day 31 (+/-1 day)
Baseline until endpoint: day 31 (+/-1 day)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart

1. februar 2016

Primær fullføring (Faktiske)

1. juli 2016

Studiet fullført (Faktiske)

1. juli 2016

Datoer for studieregistrering

Først innsendt

22. januar 2016

Først innsendt som oppfylte QC-kriteriene

8. februar 2016

Først lagt ut (Anslag)

11. februar 2016

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. september 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. september 2019

Sist bekreftet

1. juli 2016

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere